U.S. Stocks Movement: Omeros Pharmaceuticals plunges on October 16 after narsoplimab rejected again by the EU + approval stalled
Bitget异动解读2026/10/16 14:15Omeros Pharmaceuticals October 16: Major Decline Analysis
Keywords: Narsoplimab Rejected Again by EU, Approval Obstructed
On October 16, the European Medicines Agency's Committee for Medicinal Products for Human Use, after reconsideration, maintained a negative opinion on Omeros' application for EU approval of narsoplimab for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), confirming the negative stance from June 2026. The drug has not received an EU marketing recommendation, and its commercialization process in Europe is hindered.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
French bond market under pressure, economists warn of risk transmission
Refining profit margins soar, ExxonMobil (XOM.US) Q3 downstream business profit set to reach historic high
ExxonMobil stated that the rise in Q3 refining margins is expected to increase profits by about $4.5 billion, although part of the growth will be offset by falling oil prices and the timing effect of derivatives losses.
The Sri Lanka Renminbi Clearing Bank officially launched operations.
Crypto prices
More
